All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Professor Ulrich Jäger is a Professor of Hematology at Medizinische Universitsat Wien, Vienna, AT, and Head of the Clinical Department for Hematology and Hemostaseology at the Vienna General Hospital, Vienna, AT. Prof. Jäger obtained his university degree in General Internal Medicine at the University of Vienna, AT, with specialization in hematology/oncology.
His research areas of interest include lymphoproliferative diseases (leukemia and lymphoma), chronic lymphocytic leukemia, non-Hodgkin lymphoma, acute lymphocytic leukemia, antibody therapies, and autoimmune hemolytic anemias.
Positions of responsibility/awards: